Table 1 Patient’s characteristics, therapies and clinical outcome
Age (years) | N | % |
|---|---|---|
40–49 | 8 | 23 |
50–59 | 11 | 32 |
60–69 | 11 | 31 |
> 70 | 5 | 14 |
Chemotherapy | ||
Yes | 8 | 23 |
No | 27 | 77 |
Hormone therapy | ||
Start before RT | 12 | 34 |
Start after RT | 22 | 63 |
No | 1 | 3 |
Tumor size (cm) | ||
< 1 | 12 | 34 |
1–2 | 20 | 57 |
> 2 | 3 | 9 |
pTNM | ||
T1 (a-c) | 30 | 86 |
T2 | 5 | 14 |
N0 | 30 | 86 |
N1 | 5 | 14 |
M0 | 35 | 100 |
G1 | 7 | 20 |
G2 | 26 | 74 |
G3 | 2 | 6 |
Hormone receptor status | ||
Estrogen receptor+ | 35 | 100 |
Progesteron receptor+ | 35 | 100 |
Total dose (Gy) | ||
40 | 3 | 9 |
60 | 27 | 77 |
66 | 5 | 14 |
Total dose of boost (Gy) | ||
10 | 25 | 72 |
16 | 5 | 14 |
Clinical outcome | ||
Disease-free > 3 years | 14 | 40 |
Disease-free > 5 years | 18 | 52 |
Endometrial cancer | 1 | 3 |
Recurrence/metastases | 2 | 6 |